Announcements - OBI Pharma 台灣浩鼎

2018.Nov.15

Department of Health (DOH) clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in Hong Kong

2018.Nov.12

Investigational Device Exemption (IDE) for the development of OBI-888 was approved by the US Food and Drug Administration (FDA) for its use in OBI-888 Phase I cohort expansion phase

2018.Nov.02

Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in the United States

2018.Oct.29

OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in Australia

2018.Oct.01

OBI received notice from patent attorney’s office that product patent for OBI-822 named "Compound and Compositions of Carbohydrate Vaccine and Uses Thereof" has been approved by Taiwan Intellectual Property Office

2018.Sep.28

Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study

2018.Sep.20

Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”

2018.Sep.20

Clarification on the news article by Commercial Times

2018.Sep.19

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)

2018.Sep.03

OBI Pharma Inc. to attend 2018 industry forum hosted by Masterlink Securities

News

Latest News

Events

Latest events